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Association Between Aspirin Use
and Biliary Tract Cancer Survival
Biliary tract cancers (BTCs) are rare, with a worldwide inci-
dence of less than 2 per 100 000 individuals.1 The 5-year sur-
vival rate ranges from 5% to 15%, with a median survival of less
than 1 year.1 Between 60% and 70% of patients present with late-
stage disease (eg, inoperable or metastatic tumors) owing to the
lack of symptoms.2 Consequently, there is a critical need for
treatments that improve BTC survival. Aspirin has been pro-
posed as a treatment to reduce cancer mortality because it may
slow cancer growth through the inhibition of both cyclooxy-
genase 2, which promotes inflammation and cell proliferation,3
and platelet aggregation, which may slow the metastatic spread
of cancer.4 We investigated the association between postdiag-
nosis aspirin use and BTC survival.
Methods | This study was approved by the National Institutes
of Health Human Research Protection Program and the Inde-
pendent Scientific Advisory Committee of the Clinical Prac-
tice Research Datalink ([CPRD] Protocol 17_160.R), and it was
deemed exempt from patient written consent requirements
because it was conducted using deidentified data. We
obtained data, including all-cause deaths, on adult patients
diagnosed with BTC from 1990 through 2017 from the United
Kingdom’s CPRD, an electronic medical record database. We
identified cancers using Read codes for gallbladder cancer
(GBC), cholangiocarcinoma, ampulla of Vater cancer (AVC),
and overlapping lesions of the biliary tract. We excluded
patients with previous cancer, except for nonmelanoma skin
cancer.
Ever use of postdiagnosis aspirin was defined as 1 pre-
scription or more recorded in the CPRD on or after the BTC di-
agnosis date. We used Cox proportional hazards regression
models to estimate the cancer site-specific hazard ratios (HRs)
and 95% CIs for the association between time–dependent post-
diagnosis aspirin use and overall survival. Patients who re-
ceived an aspirin prescription within 30 days of diagnosis en-
tered the model as users. The time scale began at diagnosis until
death, exit from the study, or the end of follow-up (truncated
at 10 years). We adjusted for the following covariates a priori:
age at diagnosis, sex, comorbidities, statin use at diagnosis, in-
dicators of a healthy lifestyle, and year of diagnosis. We fit
separate models for each BTC type and stratified the baseline
hazard by prediagnosis aspirin use (yes/no). We estimated ad-
justed survival curves using a marginal approach to remove
the sex and age effects on aspirin use, accounting for the time-
dependent exposure.5 We conducted analyses from April to
May 2019 using SAS (version 9.4; SAS Institute) and survival
curves in R Studio (version 1.1.453).
Results | Among the eligible 2934 patients with BTC, 667 (23%)
had GBC; 1559 (53%) cholangiocarcinoma; 224 (8%) AVC; and
Table. Time-Dependent Associations Between Postdiagnosis Aspirin Use and Overall Survival for Each Biliary Tract Cancer Sitea
Gallbladder Cholangiocarcinoma Ampulla of Vater Overlapping Lesions
No. of Events/
No. at Riskb HR (95% CI)
No. of Events/
No. at Riskb HR (95% CI)
No. of Events/
No. at Riskb HR (95% CI)
No. of Events/
No. at Riskb HR (95% CI)
Overall










Nonusers 145/145 1 [Reference] 383/383 1 [Reference] 33/33 1 [Reference] 119/119 1 [Reference]








No Prediagnosis Aspirin Use
Nonusers 354/455 1 [Reference] 815/1036 1 [Reference] 83/153 1 [Reference] 241/318 1 [Reference]










.03 <.001 .005 .005
Abbreviations: BTC, biliary tract cancer; HR, hazard ratio; NA, not applicable.
a Adjusted for sex, history of heart disease, statin use (current, former, never),
presence of comorbidities, age at diagnosis, and year of diagnosis. Aspirin use
was modeled as time dependent and the baseline hazard was stratified by
prediagnosis aspirin use.
b The results presented used Cox regression where aspirin was modeled as time
dependent (eg, individuals could switch between use and nonuse status). The
numbers represent aspirin use at the time of BTC diagnosis.
c Prevalent users were defined as patients with 2 or more aspirin prescriptions
before BTC diagnosis. Incident users were defined as patients who only
initiated aspirin use on or after the BTC diagnosis date.
d P values for interaction were estimated by putting a cross-product term in the
models for postdiagnosis use and prediagnosis use.
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484 (16%) overlapping. There were 2415 deaths (82%), with
amedian survival of 5.8 (interquartile range, 2-15) months.
Two-hundred and fifty-six (9%) patients were aspirin users
at baseline, with an additional 349 (12%) patients initiating
aspirin use after diagnosis. Ninety-six percent of aspirin
users (n = 2817) were prescribed a 75-mg dose. Compared
with nonusers, aspirin users were more likely to be older,
current statin users, and prediagnosis aspirin users and
were more likely to have heart disease and comorbidities.
Aspirin use was associated with decreased risk of death
in patients with GBC (HR, 0.63; 95% CI, 0.48-0.83), cho-
langiocarcinoma (HR, 0.71; 95% CI, 0.60-0.85), AVC (HR,
0.44; 95% CI, 0.26-0.76), and overlapping BTC (HR, 0.68;
95% CI, 0.50-0.92) (Table). The survival probabilities are
shown in the Figure. Incident users with no history of aspi-
rin use had a larger benefit from postdiagnosis aspirin use
than prevalent users, although all users had a reduction in
risk of death.
Discussion | We observed a reduced risk of death for postdiag-
nosis aspirin users across all BTC types. Platelet activation pro-
tects tumor cells from elimination, enhances metastatic cell
growth, and enables cancerous cells to spread via the
bloodstream.4,6 Aspirin may slow the metastatic spread of can-
cer cells through inhibition of platelet aggregation, improv-
ing BTC survival.1 A limitation of our analysis is the lack of data
on cancer stage and chemotherapy regimens received (if any).
However, most BTCs are diagnosed at late stage2 with less than
10% of patients presenting with resectable tumors and 50%
of tumors metastasizing to the lymph nodes.1 The survival ben-
efit of aspirin observed in our study is on par with the current
standard of care.2

















































































































































































Survival curves were weighted by age and sex distributions of the cohort with aspirin use modeled as time dependent. In patients with gallbladder cancer, the
survival probabilities were for aspirin users vs nonusers were 59% (95 CI, 31%-100%) vs 27% (95% CI, 16%-47%). The survival probabilities in aspirin users vs
nonusers with cholangiocarcinoma were 62% (95% CI, 42%-98%) 26% (95% CI, 19%-35%). In patients with ampulla of Vater cancer, the survival probabilities were
85% (95% CI, 33%-83%) vs 52% (95% CI, 18%-43%) in aspirin users vs nonusers, respectively. Survival probabilities in aspirin users vs nonusers with overlapping
lesions of the biliary tract were 57% (95% CI, 34%-100%) vs 27% (95% CI, 16%-46%). Estimated survival at 1 year after diagnosis (dotted line) was calculated with
95% CIs computed based on the quantiles of the corresponding bootstrap distribution function with 1,000 replications. The numbers at risk represent individuals at
the beginning of each time point.
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COMMENT & RESPONSE
Immune-Related Adverse Events of Immune
Checkpoint Inhibitors—From a Clinical
to Pathophysiological View
To the Editor We read with great interest the article published in
JAMA Oncology by Berner and colleagues,1 which was the first
study, to our knowledge, to show a potential mechanism of
skin immune-related adverse events (irAEs) induced by
immune checkpoint inhibitors (ICIs). Clinical studies have
enhanced the understanding of irAEs in a clinical but not
pathophysiological view. This study1 found that patients with
non–small cell lung cancer who were treated with a pro-
grammed cell death 1 (PD-1) inhibitor and experienced skin
irAEs had a higher response rate and longer overall survival
than those without skin irAEs. By analyzing the T-cell recep-
tor (TCR) clones from peripheral blood mononuclear cells,
tumor biopsy specimens, and biopsy specimens from the sites
of skin irAEs, Berner et al1 revealed that some shared antigens
were present in both lung tumors and the skin. The study had
meaningful findings, and we support most of the conclusions,
but we have several concerns about the study.
First, the duration of treatment may be an important con-
founding factor that could affect the association between irAEs
and efficacy. Longer duration of ICI treatment has been asso-
ciated with a higher rate of adverse events.2 However, the treat-
ment duration was not reported in this study. Duration of treat-
ment and onset time of skin irAEs should be reported to better
explain the conclusion.
Thesecondconcernisaboutthesitefromwhichthepretreat-
ment tumor specimen was obtained for the sequencing. With a
better understanding of the temporal and spatial heterogeneity
of the tumor, the primary tumor or metastasis site and advanced
or recurrent disease provide different genomic information.3 In
lung cancer, TCR intratumor heterogeneity has been reported.4
In addition, the dynamics of changes in the complementary de-
terminingregion3ofTCRduringnivolumabtreatmenthavebeen
described.5 However, Berner et al1 did not address the site of the
tumor sample. Knowing the site of the pretreatment tumor
sample (primary tumor or metastasis) and the patients’ disease
stage (advanced or recurrent) would help us to better understand
the mechanism of skin irAEs associated with ICI therapy.
The conclusion that lung tumors and the skin share some
of the same self-antigens should be validated in larger cohort
studies. If necessary, repeat tumor biopsy specimens ob-
tained before and during treatment should be matched with
specimens from the sites of skin irAEs to confirm a patho-
physiological mechanism. Additional analysis of the patho-
physiological mechanism will improve the understanding of
irAEs, allowing clinicians to better manage them and to maxi-
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